Aquestive Therapeutics Releases Topline PK Data From Self-Administration Study Of Anaphylm; Meets Primary Endpoints With Comparable PK Whether Administered By Subjects Or HCPs; Final OAS Challenge Study Enrolling; Pre-NDA Meeting Anticipated By End Of Q3 2024
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics has released topline pharmacokinetic (PK) data from its self-administration study of Anaphylm, showing comparable results whether administered by subjects or healthcare providers. The final Oral Allergy Syndrome (OAS) challenge study is currently enrolling, and a pre-New Drug Application (NDA) meeting is anticipated by the end of Q3 2024.
July 25, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics has reported positive topline PK data for Anaphylm, showing comparable results for self-administration and HCP administration. The final OAS challenge study is enrolling, and a pre-NDA meeting is expected by Q3 2024.
The positive PK data and the progress towards a pre-NDA meeting are significant milestones for Aquestive Therapeutics. These developments are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100